Member Info for Sangijuelas1

Some buyout firms including Carlyle and Blackstone are looking at SVB US loan book.

I might be sceptical but I would imagine they are not just looking to lend but rather take over companies that can't make the interest payments.

I don't know of course. Nasdaq seems the most likely but they could even be attracted to another European market if London continues to decline.

They could actually be a buyout target for private equity wanting to get more involved in VC funding.
If that Bank of London bid for SVB UK was serious it was interesting because they are backed by Carlyle Group, a PE firm with $376bn AUM.

MV stands there independently but you could imagine a big player wanting to take over and keep current management for their knowledge, experience and connections.

That's one reason why I am in Ocado at the current price. I think someone will buy them.

I honestly don't think we are going over 700 for the foreseeable.

This is not just GROW or tech related but more to do with the woeful state of the London markets. Leaving aside their inability to look beyond dividend stocks major companies like Shell and BAT are being pressured to delist and go to the US.

Could MV benefit if large dividend payers do leave the UK market? In terms of forcing UK fund managers to look beyond their favourites. Possibly, although I think it more likely that MV themselves will have to look at delisting for Nasdaq.

Blimey Steph have you switched to Chat GPT

Not a portfolio company but good comparator for Revolut.
Pretty much forced into a fundraise due to staff options issues expiring and tax bills for previous awards.

Last round was $95bn, now valued at $50bn. Raised $6.5bn

It's not all about IPO. Molten can make money from trade sales.

Innocent smoothies never IPO'd. They were just bought by Coca Cola.

The same could happen with a company like Allplants. Build business and sell to company that buys brands like Unilever type company.

In a portfolio like this the hope is to get 1-2 big winners and enough moderates to outweigh the losers.

By the time many of the companies list or get sold most of the gains have already accumulated.

The model is to exit regardless and unless there are lock ins that's the aim. I thought it was a shame they got rid of Path but they made a lot there.

It will probably take 3-5 years for that to get up to $100.

https://www.grocerygazette.co.uk/2023/03/14/allplants-meals-launch-ocado/

Looks like selling well. Reviews on the Ocado website starting to accumulate as well.

The owners of Food for Friends restaurant in Brighton have got very rich selling lentil daal to students for a tenner a go

Also you mention 5 companies, only one of which Molten has been involved with

As for Ocado with supermarket workers have you seen the pay rises being given to supermarket staff.

They can't recruit in part because so few kids were born 15-20 years ago and we sent European workers home

Sage, writing a big block of text like that is kind of impenetrable and you jump from one point to another in the same sentence.

It would be easier to respond to you and address what you say if you could break things down a bit.

Think PowerPoint with bulletpoints style

I am not concerned about the current market fluctuations. I am looking to remain invested long term. Same with UI Path and some others I hold.

I believe the current market hysteria about bank stability (CS is incredibly well capitalised and at no risk) is an excuse to give the markets a final crash down to squeeze out retail investors before the coming upturn in tech markets now that rates are on the way to stabilising. (US farm price inflation fell substantially for the 1st time in 2 years). This is not going to be a generalised rise but quality companies with a clear path (spot the joke) to profit or at least a serious, credible opportunity will start to benefit.

The 1st question on the UI Path earnings call last night from Barclays was about AI and how Path are going to build integrations with Open AI.

We can see that with the HSBC buyout of SVB UK (retaining the board and CEO) and Barclays takeover of the Tech Nation operation there is a hunger for successful emerging companies.

And also big pharma is starting out on the acquisition trail again, with Seagen and Provention Bio taken out in the last few days and others expected to follow.

It's like vultures picking over the carcasses of the Dotcom crash looking for the Facebooks and Googles at rock bottom prices.

One deflationary factor that is being left out of the equations is the tendency for new tech to deliver productivity gains that can drive down the cost of products. With a heavily integrated global economy, much of the production price falls were reliant on labour from China and India. Now companies are going to have to make a serious return back to prioritising tech and innovation.

We are at the stage in Industry 4.0 where they are moving from talking about it to implementing it.

Product launched today
https://www.vaultree.com/press-release/vaultree-launches-software-development-kit-making-scalable-data-in-use-encryption-generally-available-to-all-enterprises/

Confirmation of the £2.5bn gov funding for Quantum Computing.

Comments from Riverlane CEO in the article
https://thequantuminsider.com/2023/03/15/quantum-community-reacts-to-uks-2-5-billion-plan-for-quantum/

Article, looking strong, references their collaboration with GM
https://www.automotiveworld.com/articles/focalpoints-software-solves-the-av-multipath-problem/

The tongue in cheek part is if they get £150m from a sale they will buy some stock.

They aren't going to get £150m from selling any of the portfolio companies.

It's down because it gets sold as part of ftse 250 Index funds, 250 down 1.5%

Low volume, there are hardly ever any buyers /sellers index of index trades

Would have been more a signal of confidence if they had bought at £4 not £3

They said they would buy own shares if there was a windfall realisation of £150m- something unlikely in the short term.
Think it was said tongue in cheek.

Endomag recently broke through to the core portfolio. Been supported for a number of years by Molten.

Nice to see portfolio companies providing benefits in the world of medicine. The article below is not a one off and I have seen similar ones praising Magseed from both the US and Australia.

They recently went a bit more vertical by stopping relying on distributors and bringing sales in house

https://www.limerickleader.ie/news/health/1056471/new-life-saving-advances-in-technology-benefitting-cancer-patients-at-university-hospital-limerick.html?utm_source=dlvr.it&utm_medium=twitter

In addition they have raised funding for Quantum Computing up to £2.5bn (maybe good for Riverlane)

And there is talk of building a UK Supercomputer maybe with Graphcore

https://www.theregister.com/AMP/2023/03/09/uk_prime_minister_wants_800m/

https://techcrunch.com/sponsor/great-britain-northern-ireland/smart-investment-starts-here-why-west-coast-venture-capitalists-are-turning-to-the-uk-2/?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAESkiE3pPiOsSTlURn4a6Mx5puhfRFsv0sm1WOtOz6tCKYH-_vamPAS6oDmDUIlRKkd7NHlOG_aLD4Uk4UWzuSXzXJENrTEwqVvh3rr8XvAVztLkD1Tg5x_fh836rOySpoJJH4w9pj8-4cHbAVO7MpgxD1g4wHJtbMT_rL-uyh3D

From the Department of Business and Trade